RecruitingPhase 1Phase 2NCT04210492

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

Phase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

Sponsor

Yale University

Enrollment

36 participants

Start Date

Aug 26, 2020

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether delivering radiation therapy in 3 larger doses (stereotactic body radiotherapy) instead of the standard number of sessions can safely and effectively treat centrally located lung tumors near major airways or blood vessels. **You may be eligible if...** - You have a lung tumor that is 5 cm or smaller - The tumor is centrally located (near major airways, blood vessels, the esophagus, or the heart) - You are scheduled for stereotactic body radiotherapy (SBRT) **You may NOT be eligible if...** - Your tumor is larger than 5 cm - Your tumor is not centrally located near critical structures - You cannot tolerate the required radiation dose constraints Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.